Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ERIC 2024 | Looking forward to the 2024 ERIC International Meeting

Lydia Scarfò • 22 Jul 2024
ERIC 2024
Chronic Lymphocytic Leukemia Leukemia

Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, shares her excitement about this year’s European Research Initiative on CLL (ERIC) International Meeting. The event, taking place in Barcelona, Spain, from September 26-28, 2024, will delve into the latest advancements in the understanding and treatment of chronic lymphocytic leukemia (CLL). This interview was recorded virtually.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Lydia Scarfò

From fixed-duration regimens to novel agents: current & future perspectives on CLL treatment 2:34
From fixed-duration regimens to novel agents: current & future perspectives on CLL treatment
Lydia Scarfò • 4 Sep 2025
MRD assessment in CLL: importance of standardizing tests & potential clinical application 3:04
MRD assessment in CLL: importance of standardizing tests & potential clinical application
Lydia Scarfò • 4 Sep 2025
Tailoring therapy for younger, fit patients with CLL: advice for community oncologists 2:17
Tailoring therapy for younger, fit patients with CLL: advice for community oncologists
Lydia Scarfò • 5 Sep 2025
The importance of integrating genetic profiling in CLL: from NGS to emerging biomarkers 1:39
The importance of integrating genetic profiling in CLL: from NGS to emerging biomarkers
Lydia Scarfò • 4 Sep 2025

Related Videos

HARMONY Alliance study: validation of MRD as a surrogate endpoint in AML 8:00
HARMONY Alliance study: validation of MRD as a surrogate endpoint in AML
Jesse Tettero • 6 Dec 2025
POD36 as a prognostic marker and clinical tool in frontline CLL 3:03
POD36 as a prognostic marker and clinical tool in frontline CLL
Paul Hampel • 8 Dec 2025
AI‑driven virtual tumor board enhances precision care in AML: refining AI use in hematology 7:37
AI‑driven virtual tumor board enhances precision care in AML: refining AI use in hematology
David Swoboda • 5 Dec 2025
Recent advancements in the understanding of Richter’s transformation 1:00
Recent advancements in the understanding of Richter’s transformation
Elisa ten Hacken • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals